JPRN-jRCT2031230272RecruitingPhase 1
A phase I, open-label, single-dose, randomized, cross-over study to evaluate BLZ945 granule for suspension in healthy participants: relative bioavailability in comparison to BLZ945 capsule and food effect
Yamada Hiroyuki0 sites54 target enrollmentStarted: August 1, 2023Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- Enrollment
- 54
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- >= 18age old to <= 55age old (—)
- Sex
- All
Inclusion Criteria
- •Japanese healthy male and female 18 to 55 years of age, inclusive, and in good health as determined by past medical history, physical examination, vital signs, 12-lead ECG, and laboratory tests at screening and initial baseline.
- •- Participants must weigh at least 40.0 kg to participate in the study and must have a Body Mass Index (BMI) within the range of 18-30 kg/m2 at screening.
- •- At screening and initial baseline, vital signs (body temperature, systolic and diastolic blood pressure and pulse rate) will be assessed in the sitting position after the participant has rested at least 3 minutes. Sitting vital signs should be within the following ranges:
- •- Axillary body temperature, 35.0-37.5 degree
- •- Systolic blood pressure, 90-139 mm Hg
- •- Diastolic blood pressure, 50-89 mm Hg
- •- Pulse rate, 40-90 bpm
Exclusion Criteria
- •- Use of any prescription drugs or herbal supplements within 4 weeks prior to initial dosing, and/or over-the-counter (OTC) medication or dietary supplements (vitamins included) within 2 weeks prior to initial dosing.
- •- Significant illness, including infectious diseases that has not resolved within 30 days prior to baseline, or positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) test results at screening or baseline, or contact with a known case of Coronavirus Disease 2019 (COVID-19) infection in the 2 weeks prior to baseline.
- •- Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during the study and for 14 days after stopping study treatment.
- •- Sexually active males unwilling to use a condom during intercourse during the study and for 14 days after stopping study treatment. A condom is required for all sexually active male participants to prevent them from fathering a child AND to prevent delivery of study treatment via seminal fluid to their partner. In addition, male participants must not donate sperm for the time period specified above.
- •- Participants unwilling to comply with lifestyle restrictions during the study period.
Investigators
Similar Trials
Completed
Not Applicable
A phase I, open-label, single-dose, randomized, cross-over, 3 parts study to evaluate in healthy subjects the relative bioavailability of eltrombopag new capsule formulation (CPS) in comparison to the reference marketed film-coated tablets (FCT) (Part 1), the pharmacokinetic comparability of eltrombopag CPS and marketed FCT (Part 2) and the effect of food on the pharmacokinetics of eltrombopag administered as CPS (Part 3)thrombocytopeniaNL-OMON49500ovartis248
Completed
Not Applicable
A Phase 1, Open-label, Single-dose, Randomized, Crossover Study to Assess the Local Tolerability of the Tildrakizumab 200 mg Dose when Delivered as Single Subcutaneous Injection via the 200 mg/2 mL Pre-filled SyringePsoriasis10014982NL-OMON49835Almirall42
Completed
Not Applicable
A Phase I, open-label, randomized, single-dose, two-way crossover study to compare the relative bioavailability of GLPG2737 given as a capsule formulation and an oral suspensioCystic fibrosismucoviscidosisthick mucus disease10027664NL-OMON45861Galapagos NV12
Completed
Phase 1
A study to measure how much of the study drug GDC-6036 is absorbed and the effect of food on absorption in healthy participantsISRCTN10450075Genentech, Inc.18
Completed
Phase 1
A study to investigate the effects of food and administration of different forms of mavodelpar on the safety and concentration of mavodelpar in the bloodHealthy VolunteersISRCTN85791974Reneo Pharma Ltd (United Kingdom)32